Derek Ostertag

1.4k total citations
35 papers, 736 citations indexed

About

Derek Ostertag is a scholar working on Genetics, Genetics and Molecular Biology. According to data from OpenAlex, Derek Ostertag has authored 35 papers receiving a total of 736 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Genetics, 15 papers in Genetics and 14 papers in Molecular Biology. Recurrent topics in Derek Ostertag's work include Virus-based gene therapy research (21 papers), Glioma Diagnosis and Treatment (15 papers) and Cancer Research and Treatments (12 papers). Derek Ostertag is often cited by papers focused on Virus-based gene therapy research (21 papers), Glioma Diagnosis and Treatment (15 papers) and Cancer Research and Treatments (12 papers). Derek Ostertag collaborates with scholars based in United States, Austria and India. Derek Ostertag's co-authors include Jacques Perrault, Lufen Chang, Yi Chen, Michael Karin, Wen-Ming Chu, Bryan Williams, Zhi-Wei Li, Yinling Hu, Douglas J. Jolly and Harry E. Gruber and has published in prestigious journals such as Journal of Clinical Oncology, Immunity and Cancer Research.

In The Last Decade

Derek Ostertag

29 papers receiving 704 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Derek Ostertag United States	11	341	325	259	252	122	35	736
Jayson Hardcastle United States	10	353 1.0×	237 0.7×	572 2.2×	475 1.9×	34 0.3×	11	853
Luke Russell United States	11	294 0.9×	172 0.5×	370 1.4×	329 1.3×	36 0.3×	19	648
Natalia Savelyeva United Kingdom	16	353 1.0×	461 1.4×	60 0.2×	237 0.9×	50 0.4×	28	835
Jason Debasitis United States	3	286 0.8×	110 0.3×	129 0.5×	125 0.5×	53 0.4×	3	458
Sophia Z. Shalhout United States	11	314 0.9×	164 0.5×	226 0.9×	366 1.5×	50 0.4×	41	748
Daniel Öberg Sweden	13	374 1.1×	91 0.3×	273 1.1×	180 0.7×	60 0.5×	16	620
Miika Martikainen Finland	11	200 0.6×	198 0.6×	297 1.1×	272 1.1×	24 0.2×	14	661
Johanna K. Kaufmann Germany	13	451 1.3×	325 1.0×	497 1.9×	551 2.2×	33 0.3×	26	1.0k
Laura Evgin United States	16	378 1.1×	261 0.8×	646 2.5×	639 2.5×	40 0.3×	28	987
Mani Larijani Canada	22	575 1.7×	656 2.0×	125 0.5×	139 0.6×	60 0.5×	48	1.2k

Countries citing papers authored by Derek Ostertag

Since Specialization

Citations

This map shows the geographic impact of Derek Ostertag's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Derek Ostertag with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Derek Ostertag more than expected).

Fields of papers citing papers by Derek Ostertag

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Derek Ostertag. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Derek Ostertag. The network helps show where Derek Ostertag may publish in the future.

Co-authorship network of co-authors of Derek Ostertag

This figure shows the co-authorship network connecting the top 25 collaborators of Derek Ostertag. A scholar is included among the top collaborators of Derek Ostertag based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Derek Ostertag. Derek Ostertag is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Merchan, Jaime R., Jordi Rodon, Shree Venkat, et al.. (2025). A phase 1B trial of vocimagene amiretrorepvec in patients with advanced solid tumors: Safety, tumor homing, and immune modulatory effects. Molecular Therapy. 33(11). 5505–5515.

Collins, Sara, Ashish H. Shah, Derek Ostertag, Noriyuki Kasahara, & Douglas J. Jolly. (2021). Clinical development of retroviral replicating vector Toca 511 for gene therapy of cancer. Expert Opinion on Biological Therapy. 21(9). 1199–1214. 21 indexed citations

Accomando, William P., Daniel J. Hogan, Aaron M. Newman, et al.. (2020). Molecular and Immunologic Signatures are Related to Clinical Benefit from Treatment with Vocimagene Amiretrorepvec (Toca 511) and 5-Fluorocytosine (Toca FC) in Patients with Glioma. Clinical Cancer Research. 26(23). 6176–6186. 17 indexed citations

Hogan, Daniel J., Jay‐Jiguang Zhu, Oscar R. Diago, et al.. (2018). Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients. Clinical Cancer Research. 24(19). 4680–4693. 23 indexed citations

Merchan, Jaime R., Jordi Rodón, Gerald S. Falchook, et al.. (2018). Toca 6: A phase 1b study of Toca 511 and Toca FC in patients with advanced solid tumors or lymphoma.. Journal of Clinical Oncology. 36(15_suppl). TPS2613–TPS2613. 1 indexed citations

Merchan, Jaime R., et al.. (2018). Toca 511 and Toca FC in patients with gastrointestinal tumors in the Toca 6 study.. Journal of Clinical Oncology. 36(4_suppl). TPS880–TPS880.

Hiraoka, Kei, Akihito Inagaki, Tiffany Huang, et al.. (2017). Retroviral replicating vector–mediated gene therapy achieves long-term control of tumor recurrence and leads to durable anticancer immunity. Neuro-Oncology. 19(7). 918–929. 37 indexed citations

Cloughesy, Timothy F., Derek Ostertag, Joseph Landolfi, et al.. (2017). Durable complete responses observed in IDH1 mutated high grade glioma at first recurrence undergoing treatment with Toca 511 and Toca FC.. Journal of Clinical Oncology. 35(15_suppl). e13504–e13504. 1 indexed citations

Zadeh, Gelareh, Daniela A. Bota, David Cachia, et al.. (2016). PC3 - 151 Toca 5: A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined with Toca FC versus Standard of Care in Patients Undergoing Planned Resection for Recurrent Glioblastoma (GBM) or Anaplastic Astrocytoma (AA) (NCT02414165). Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 43(S4). S17–S17. 2 indexed citations

10.

Kalkanis, Steven N., Manish K. Aghi, George Kaptain, et al.. (2015). DDEL-06PRELIMINARY SAFETY OF TOCA 511, A RETROVIRAL REPLICATING VECTOR, IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA ACROSS THREE SEPARATE PHASE 1 STUDIES. Neuro-Oncology. 17(suppl 5). v74.2–v74. 3 indexed citations

11.

Vogelbaum, Michael A., Santosh Kesari, Steven N. Kalkanis, et al.. (2015). SURG-09RESULTS OF A DOSE ESCALATION TRIAL OF TOCA 511 WITH TOCA FC IN RECURRENT HGG UNDERGOING REPEAT RESECTION. Neuro-Oncology. 17(suppl 5). v216.1–v216. 1 indexed citations

12.

Twitty, Chris, Oscar R. Diago, Daniel J. Hogan, et al.. (2015). Retroviral Replicating Vectors Deliver Cytosine Deaminase Leading to Targeted 5-Fluorouracil-Mediated Cytotoxicity in Multiple Human Cancer Types. Human Gene Therapy Methods. 27(1). 17–31. 27 indexed citations

13.

Huang, Tiffany, Ryan Burnett, Oscar R. Diago, et al.. (2014). Intravenous Administration of Retroviral Replicating Vector, Toca 511, Demonstrates Therapeutic Efficacy in Orthotopic Immune-Competent Mouse Glioma Model. Human Gene Therapy. 26(2). 82–93. 49 indexed citations

14.

Kalkanis, Steven N., Doug J. Jolly, Derek Ostertag, et al.. (2014). AT-29 * INTRAVENOUS ADMINISTRATION OF TOCA 511 IN PATIENTS WITH RECURRENT GLIOBLASTOMA. Neuro-Oncology. 16(suppl 5). v15–v15. 2 indexed citations

15.

Rodriguez-Aguirre, Maria E., Tiffany Huang, Carlos E. Ibañez, et al.. (2014). Abstract 708: Toca 511 gene therapy in combination with 5-fluorocytosine for intratumoral production of 5-fluorouracil in a colon cancer metastasis model. Cancer Research. 74(19_Supplement). 708–708. 1 indexed citations

16.

Lin, Amy, Christopher R. Logg, Yanzheng Liu, et al.. (2014). MicroRNA 142-3p Attenuates Spread of Replicating Retroviral Vector in Hematopoietic Lineage-Derived Cells While Maintaining an Antiviral Immune Response. Human Gene Therapy. 25(8). 759–771. 4 indexed citations

17.

Huang, Tiffany, Juraj Hlavatý, Derek Ostertag, et al.. (2013). Toca 511 gene transfer and 5-fluorocytosine in combination with temozolomide demonstrates synergistic therapeutic efficacy in a temozolomide-sensitive glioblastoma model. Cancer Gene Therapy. 20(10). 544–551. 45 indexed citations

18.

Ostertag, Derek, Karin Amundson, Ana Paula da Silva, et al.. (2011). Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector. Neuro-Oncology. 14(2). 145–159. 110 indexed citations

19.

Robbins, Joan M., Derek Ostertag, Karin Amundson, et al.. (2010). Intratumoral conversion of flucytosine to 5-fluorouracil using a novel MLV-based replication-competent retroviral vector carrying the cytosine deaminase gene (Toca 511) in an immune-competent model of glioblastoma.. Journal of Clinical Oncology. 28(15_suppl). e13541–e13541. 1 indexed citations

20.

Chu, Wen-Ming, Derek Ostertag, Zhi-Wei Li, et al.. (1999). JNK2 and IKKβ Are Required for Activating the Innate Response to Viral Infection. Immunity. 11(6). 721–731. 327 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact